Why treat mHSPC early with ERLEADA®?
Early treatment decisions are key to pushing back on disease progression[1]
Progression from mHSPC to mCRPC could take less than 1 year[1]a
Once patients progress to mCRPC, prognosis is poor[2]
2021 EAU guidelines: do not offer ADT alone to patients whose first presentation is M1 disease and who are willing to have and eligible for combination therapy[3]
Treating mHSPC patients early with ERLEADA® + ADT is associated with a lower frequency of AR aberrations relative to placebo + ADT[4][5]
The TITAN final analysis emphasises the benefit of early, potent, AR-signalling inhibition with ERLEADA® at the time of initial ADT for mHSPC and before progression to mCRPC.[1]
- Patients with AR aberrations at the end of treatment had worse outcomes vs. patients without[4]
- ERLEADA® + ADT was associated with decreased frequency of AR aberrations at the end of treatment vs. placebo + ADT[4][5]
Taken together, these findings suggest that early ERLEADA® + ADT provides long-term benefits vs. placebo + ADT without increased development of AR aberrations.[4]
aIn a Phase III study including patients with mHSPC on placebo + ADT.[1]
In mHSPC, early treatment decisions are key to pushing back on disease progression[1]
What if you could delay your patients’ progression to castration resistance and extend their lives?
Treat early with ERLEADA® + ADT to prolong survival & delay progression[1]
Treating early with ERLEADA® + ADT provides an additional treatment option for mHSPC patients[1]
Treating early with ERLEADA® + ADT helps maintain QoL[1]
Abbreviations
ADT, androgen deprivation therapy. AR, androgen receptor. EAU, European Association of Urology. M1, metastasised outside the pelvis. mCRPC, metastatic castration-resistant prostate cancer. mHSPC, metastatic hormone-sensitive prostate cancer. QoL, quality of life.
▼ Este medicamento está sujeito a monitorização adicional. Titular da Autorização de Introdução no Mercado: Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Bélgica.
Para mais informações deverá contactar o Representante do Titular da Autorização de Introdução no Mercado: Janssen-Cilag Farmacêutica, Lda.
Medicamento de receita médica restrita, de utilização reservada a certos meios especializados.
Antes de prescrever consulte o RCM completo.
RCM de Erleada®, veja aqui
